147 related articles for article (PubMed ID: 37766881)
21. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
22. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
23. Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus.
Fasola EL; Fasching CE; Peterson LR
J Lab Clin Med; 1995 Feb; 125(2):200-11. PubMed ID: 7844469
[TBL] [Abstract][Full Text] [Related]
24. Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against
Wang L; Chen Y; Han R; Huang Z; Zhang X; Hu F; Yang F
Infect Drug Resist; 2021; 14():3971-3977. PubMed ID: 34611414
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis.
Lan SH; Chao CM; Chang SP; Lu LC; Lai CC
Surg Infect (Larchmt); 2021 Oct; 22(8):763-770. PubMed ID: 33625294
[No Abstract] [Full Text] [Related]
26. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
Greenberg RN; Reilly PM; Weinandt WJ; Bollinger M; Kennedy DJ
Clin Ther; 1987; 10(1):52-6. PubMed ID: 3329965
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection.
Lv Q; Deng Y; Zhu X; Ruan J; Chen L
J Coll Physicians Surg Pak; 2020 Mar; 30(3):332-334. PubMed ID: 32169149
[TBL] [Abstract][Full Text] [Related]
28. Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: A retrospective case-control study.
Wang Q; Liang P; Xu Y; Yuan B; Lan C; Yan X; Li L
Eur J Clin Pharmacol; 2024 May; 80(5):737-746. PubMed ID: 38353692
[TBL] [Abstract][Full Text] [Related]
29.
Li T; Sheng M; Gu T; Zhang Y; Yirepanjiang A; Li Y
J Thorac Dis; 2018 Mar; 10(3):1370-1376. PubMed ID: 29707286
[TBL] [Abstract][Full Text] [Related]
30. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
[TBL] [Abstract][Full Text] [Related]
31. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
32. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Gao C; Tong J; Yu K; Sun Z; An R; Du Z
Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
[TBL] [Abstract][Full Text] [Related]
33. Use of cefoperazone/sulbactam in neonates.
Ovali F; Gursoy T; Sari I; Divrikli D; Aktas A
Pediatr Int; 2012 Feb; 54(1):60-3. PubMed ID: 21883691
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
35. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
[TBL] [Abstract][Full Text] [Related]
36. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
37. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.
Lin C; Tan M; Wang D; Gu C; Wu Y; Wang S
Pharmacology; 2023; 108(6):540-549. PubMed ID: 37751720
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
39. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.
Crosby MA; Gump DW
Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451
[TBL] [Abstract][Full Text] [Related]
40. Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Frontiers Production Office
Front Pharmacol; 2024; 15():1365927. PubMed ID: 38288439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
